General Information

General Information

Enobosarm is a nonsteroidal SARM that increases muscle mass with only limited effects on seminal vesicles in preclinical studies. Trials in healthy elderly men and in cancer patients with muscle wasting have reported increased lean body mass and improved physical function compared with placebo, making this compound a strong candidate for further clinical development.

Enobosarm, also known as ostarine, MK-2866, is an investigational Selective Androgen Receptor Modulator (SARM) developed for the treatment of conditions such as muscle wasting and osteoporosis, formerly under development by GTx Inc and then Merck & Company.

SARMs have been proposed as treatments of choice for various diseases, including muscle-wasting, breast cancer, and osteoporosis.

Muscle wasting is associated with significant morbidity and mortality. The potential risk profile of testosterone replacement therapy and anabolic steroids limits their clinical use for a variety of indications that may otherwise benefit from increasing lean mass, improved physical function, and improved insulin resistance. SARMs in various stages of preclinical and clinical drug development offer an important option to meet these unmet medical needs.

Ostarine is an investigational drug that has not yet been approved by the US Food and Drug Administration (FDA)

Ostarine is used by mouth, subcutaneous injection to improve muscle wasting, osteoporosis and involuntary weight loss in people who are very ill, also known as cachexia or wasting syndrome.